Literature DB >> 27262099

Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options.

Saad A Khan1, Sandi L Pruitt2, Lei Xuan3, David E Gerber1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27262099      PMCID： PMC5656433          DOI： 10.1001/jamaoncol.2016.2238

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  3 in total

1.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

2.  Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

Authors:  Douglas B Johnson; Ryan J Sullivan; Patrick A Ott; Matteo S Carlino; Nikhil I Khushalani; Fei Ye; Alexander Guminski; Igor Puzanov; Donald P Lawrence; Elizabeth I Buchbinder; Tejaswi Mudigonda; Kristen Spencer; Carolin Bender; Jenny Lee; Howard L Kaufman; Alexander M Menzies; Jessica C Hassel; Janice M Mehnert; Jeffrey A Sosman; Georgina V Long; Joseph I Clark
Journal:  JAMA Oncol       Date:  2016-02       Impact factor: 31.777

3.  Risks of myeloid malignancies in patients with autoimmune conditions.

Authors:  L A Anderson; R M Pfeiffer; O Landgren; S Gadalla; S I Berndt; E A Engels
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640
  3 in total
  42 in total

1.  Phase I study of veliparib in combination with gemcitabine.

Authors:  Ronald Stoller; John C Schmitz; Fei Ding; Shannon Puhalla; Chandra P Belani; Leonard Appleman; Yan Lin; Yixing Jiang; Salah Almokadem; Daniel Petro; Julianne Holleran; Brian F Kiesel; R Ken Czambel; Benedito A Carneiro; Emmanuel Kontopodis; Pamela A Hershberger; Madani Rachid; Alice Chen; Edward Chu; Jan H Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2017-08-02       Impact factor: 3.333

2.  Autoimmunity and Cancer, the Paradox Comorbidities Challenging Therapy in the Context of Preexisting Autoimmunity.

Authors:  Julio C Valencia; Nkolika Egbukichi; Rebecca A Erwin-Cohen
Journal:  J Interferon Cytokine Res       Date:  2018-12-18       Impact factor: 2.607

Review 3.  Immune checkpoint inhibitors in challenging populations.

Authors:  Douglas B Johnson; Ryan J Sullivan; Alexander M Menzies
Journal:  Cancer       Date:  2017-02-27       Impact factor: 6.860

Review 4.  Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis.

Authors:  Mitchell S von Itzstein; Shaheen Khan; David E Gerber
Journal:  Clin Chem       Date:  2020-06-01       Impact factor: 8.327

5.  Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).

Authors:  David E Gerber; James J Urbanic; Corey Langer; Chen Hu; I-Fen Chang; Bo Lu; Benjamin Movsas; Robert Jeraj; Walter J Curran; Jeffrey D Bradley
Journal:  Clin Lung Cancer       Date:  2016-10-26       Impact factor: 4.785

6.  Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.

Authors:  Sandra Garcia; Ajit Bisen; Jingsheng Yan; Xian-Jin Xie; Suresh Ramalingam; Joan H Schiller; David H Johnson; David E Gerber
Journal:  J Thorac Oncol       Date:  2017-08-09       Impact factor: 15.609

7.  How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.

Authors:  Saad A Khan; Sandi L Pruitt; Lei Xuan; Una Makris; David E Gerber
Journal:  Lung Cancer       Date:  2017-11-24       Impact factor: 5.705

8.  Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.

Authors:  Alessio Cortellini; Sebastiano Buti; Daniele Santini; Fabiana Perrone; Raffaele Giusti; Marcello Tiseo; Melissa Bersanelli; Maria Michiara; Antonino Grassadonia; Davide Brocco; Nicola Tinari; Michele De Tursi; Federica Zoratto; Enzo Veltri; Riccardo Marconcini; Francesco Malorgio; Carlo Garufi; Marco Russano; Cecilia Anesi; Tea Zeppola; Marco Filetti; Paolo Marchetti; Andrea Botticelli; Gian Carlo Antonini Cappellini; Federica De Galitiis; Maria Giuseppa Vitale; Roberto Sabbatini; Sergio Bracarda; Rossana Berardi; Silvia Rinaldi; Marianna Tudini; Rosa Rita Silva; Annagrazia Pireddu; Francesco Atzori; Rita Chiari; Biagio Ricciuti; Daniela Iacono; Maria Rita Migliorino; Antonio Rossi; Giampiero Porzio; Katia Cannita; Valeria Ciciarelli; Maria Concetta Fargnoli; Paolo Antonio Ascierto; Corrado Ficorella
Journal:  Oncologist       Date:  2019-02-22

9.  Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers.

Authors:  Muhammad Shaalan Beg; Jeffrey Meyer
Journal:  J Gastrointest Oncol       Date:  2018-02

10.  Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.

Authors:  Christina S Baik; Eric H Rubin; Patrick M Forde; Janice M Mehnert; Deborah Collyar; Marcus O Butler; Erica L Dixon; Laura Q M Chow
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.